End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.05 DKK | 0.00% | +0.50% | -43.38% |
Apr. 16 | Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients | CI |
Apr. 12 | Curasight A/S Announces Board Changes | CI |
Sales 2024 * | - | Sales 2025 * | 43M 6.14M | Capitalization | 200M 28.56M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 35M 5M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.65 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
1 week | +0.50% | ||
Current month | -7.80% | ||
1 month | -13.36% | ||
3 months | -46.40% | ||
6 months | -45.08% | ||
Current year | -43.38% |
Managers | Title | Age | Since |
---|---|---|---|
Carsten Nielsen
FOU | Founder | 41 | 12-12-31 |
Jacob Madsen
FOU | Founder | 52 | 12-12-31 |
Andreas Kjaer
FOU | Founder | 61 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kirsten Drejer
BRD | Director/Board Member | 68 | 21-05-03 |
Per Falholt
CHM | Chairman | 65 | 19-12-31 |
Chief Executive Officer | 57 | 15-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 10.05 | 0.00% | 1,167 |
24-04-18 | 10.05 | -0.99% | 1,455 |
24-04-17 | 10.15 | -1.93% | 9,538 |
24-04-16 | 10.35 | +3.50% | 3,645 |
24-04-15 | 10 | 0.00% | 913 |
End-of-day quote NORDIC GROWTH MARKET, April 18, 2024
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.38% | 28.57M | |
-1.42% | 41.52B | |
+42.15% | 39.9B | |
+1.97% | 38.83B | |
-14.19% | 26.05B | |
+1.82% | 23.78B | |
-24.55% | 18.26B | |
-4.07% | 11.65B | |
+21.36% | 11.53B | |
+8.20% | 11.2B |
- Stock Market
- Equities
- CURAS Stock